The Role of Toll-like Receptor-4 in Periodontitis Patients With End-stage Renal Disease in a Sample of Egyptian Population
Launched by AIN SHAMS UNIVERSITY · Dec 31, 2024
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how a specific gene, called TLR4, might be linked to gum disease (periodontitis) in people who have severe kidney failure, known as end-stage renal disease (ESRD). The study focuses on patients in Egypt and aims to understand if changes in this gene affect the chances of having both kidney disease and gum problems. Since inflammation is a common factor in both conditions, researchers want to see if certain genetic differences make some people more likely to suffer from these health issues together.
People who may join the study include adults aged 30 to 60 who have moderate to severe gum disease. The trial has two groups: one group of healthy individuals with gum disease but no other health problems, and another group of patients who have ESRD, are on regular dialysis treatment, have gum disease, and also have type 2 diabetes. Smokers and those with other serious health conditions are not eligible to participate. If you join, you can expect to have your genetic information studied and health assessments related to your gums and kidney disease. This research could help doctors better understand how genetics influence these conditions and possibly improve future treatments.
Gender
ALL
Eligibility criteria
- • Group I: Healthy Subjects with Periodontitis
- Inclusion Criteria:
- • Age: 30 to 60 years
- • Gender: Both male and female
- • Diagnosed with Periodontitis stage II and/or stage III
- • Systemically healthy, no history of systemic diseases
- • Not on long-term medications
- Exclusion Criteria:
- • Smokers
- • Individuals with any systemic disease or long-term medication use
- • Group II: ESRD Patients with Periodontitis
- Inclusion Criteria:
- • Age: 30 to 60 years
- • Gender: Both male and female
- • Diagnosed with end-stage renal disease (ESRD) on regular hemodialysis
- • Diagnosed with Periodontitis stage II and/or stage III
- • Unrelated Egyptians from a similar socioeconomic status, residing in the same geographical area
- • Underlying type 2 diabetes mellitus
- Exclusion Criteria:
- • Individuals with kidney transplants
- • Individuals with systemic diseases other than diabetes
- • History of malignancy
- • Smokers
About Ain Shams University
Ain Shams University, established in Cairo, Egypt, is a prestigious higher education institution renowned for its commitment to academic excellence and research innovation. As a clinical trial sponsor, the university leverages its extensive resources and expertise in various medical and scientific disciplines to advance healthcare through rigorous research initiatives. With a focus on ethical practices and adherence to regulatory standards, Ain Shams University aims to contribute to the development of new therapies and improve patient outcomes, fostering collaboration among researchers, healthcare professionals, and industry partners in the pursuit of medical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Fayoum, , Egypt
Patients applied
Trial Officials
Fatma E. A. Hassanein, PHD
Principal Investigator
king Salman Intwenational University University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported